losartan has been researched along with rosiglitazone in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 14 (66.67) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Boisbrun, M; Dupuis, F; Flament, S; Foulquier, S; Grillier-Vuissoz, I; Grimaud, L; Henrion, D; Lartaud, I; Meyer, M; Monard, G | 1 |
| Norman, BH | 1 |
| Avery, MA; Benson, SC; Chittiboyina, A; Desai, P; Ho, CI; Kurtz, TW; Pershadsingh, HA; Pravenec, M; Qi, N; Wang, J | 1 |
| Axelsson, J; Ayala, ER; Lindholm, B; Qian, JQ; Stenvinkel, P; Yao, Q | 1 |
| Caballero-Hidalgo, A; Hernandez-Trujillo, Y; Macias-Reyes, A; Rodriguez-Esparragon, F; Rodriguez-Perez, JC | 1 |
| Chan, LY; Lai, KN; Leung, JC; Tang, SC; Xiao, J | 1 |
| Chan, LY; Guo, H; Lai, KN; Leung, JC; Tang, SC | 1 |
| Harrison, SA; Jones, FJ; Shaw, JC; Torres, DM; Ward, JA; Williams, CD | 1 |
| Chalasani, N; Corey, KE | 1 |
| Cao, H; Cheng, YN; Dong, X; Dong, YN; Guo, XL; Sun, R; Wu, Y; Yang, KM; Yu, LG | 1 |
| Ateyya, H; El-Sherbeeny, NA; Nader, MA | 1 |
2 review(s) available for losartan and rosiglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
1 trial(s) available for losartan and rosiglitazone
| Article | Year |
|---|---|
Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial.
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Biopsy; Drug Therapy, Combination; Fatty Liver; Female; Humans; Hypoglycemic Agents; Liver; Losartan; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Young Adult | 2011 |
18 other study(ies) available for losartan and rosiglitazone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Synthesis and evaluation of new designed multiple ligands directed towards both peroxisome proliferator-activated receptor-γ and angiotensin II type 1 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Chromans; Drug Design; Humans; Imidazoles; Ligands; Male; MCF-7 Cells; Molecular Docking Simulation; PPAR gamma; Rats, Wistar; Receptor, Angiotensin, Type 1; Triazoles | 2018 |
Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Cell Differentiation; Cells, Cultured; Chlorocebus aethiops; Drug Evaluation, Preclinical; Gene Expression Regulation; Imidazoles; Insulin; Irbesartan; Losartan; Male; Mice; Models, Molecular; Myoblasts; Protein Conformation; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Structure-Activity Relationship; Telmisartan; Tetrazoles; Thiazoles; Thiazolidinediones; Thiazolidines; Transcription Factors; Triglycerides; Valine; Valsartan; Weight Gain | 2004 |
A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells.
Topics: Angiotensin Receptor Antagonists; Cells, Cultured; Epithelium; Glucose; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Losartan; Peritoneum; PPAR gamma; Rosiglitazone; Signal Transduction; Smad7 Protein; Thiazolidinediones; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2007 |
Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model.
Topics: Animals; Aryldialkylphosphatase; Atherosclerosis; Carboxylic Ester Hydrolases; CD36 Antigens; Cholesterol, Dietary; Gene Expression Regulation; Lipid Peroxidation; Lipid Peroxides; Lipids; Losartan; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2008 |
Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Blotting, Western; Cells, Cultured; Culture Media, Conditioned; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation; Glomerulonephritis, IGA; Humans; Immunoglobulin A; Intercellular Adhesion Molecule-1; Interleukin-6; Kidney Tubules; Losartan; Male; Mesangial Cells; NF-kappa B; PPAR gamma; Receptor Cross-Talk; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2009 |
Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Drug Therapy, Combination; gamma-Globulins; Glomerulonephritis, IGA; Intercellular Adhesion Molecule-1; Kidney; Leukocytes, Mononuclear; Losartan; Mesangial Cells; Nephrectomy; PPAR gamma; Proteinuria; Rats; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Rosiglitazone; Thiazolidinediones; Transforming Growth Factor beta | 2011 |
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
Topics: Fatty Liver; Female; Humans; Losartan; Male; Metformin; Non-alcoholic Fatty Liver Disease; Rosiglitazone; Thiazolidinediones | 2011 |
Inhibition of PTEN expression and activity by angiotensin II induces proliferation and migration of vascular smooth muscle cells.
Topics: Adenoviridae; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Cell Movement; Cell Proliferation; Focal Adhesion Kinase 1; Gene Expression Regulation; Losartan; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Rats; Rosiglitazone; Signal Transduction; Sulfones; Thiazolidinediones; Tissue Culture Techniques; Transduction, Genetic; Vasodilator Agents | 2013 |
Beneficial effects of rosiglitazone and losartan combination in diabetic rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antioxidants; Aorta; Diabetes Mellitus, Experimental; Drug Interactions; Losartan; Male; Oxidative Stress; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2018 |